Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  Akt inhibitor GSK2141795
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2013-01320, SWOG-S1221, S1221, U10CA180888, U10CA032102, NCT01902173
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01354, NCI 9443, 2013-0001, 9443, N01CM00039, N01CM00071, P30CA016672, NCT01907815
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01659, GOG-0229O, U10CA180868, U10CA027469, NCT01935973
A Study of Trametinib and GSK2141795 Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PHL-091 / NCI 9460, NCT01951495
GSK1120212+GSK2141795 for Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-334, NCT01958112
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01895, 2013C0069, NCI 9455, OSU 13117, 9455, N01CM00070, N01CM00100, P30CA016058, NCT01964924
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-02091, 13-144, 9445, N01CM00039, P30CA008748, NCT01979523
Start Over